Arno Therapeutics, Inc. expected to report Q3 2010 results on November 14, 2010. This event was calculated by Capital IQ (Created on August 31, 2010).

Arno Therapeutics, Inc. expected to report Fiscal Year 2010 results on March 31, 2011. This event was calculated by Capital IQ (Created on June 27, 2010).

Arno Therapeutics, Inc. announced the dosing of the first patient in an investigator sponsored Phase I/IIa clinical study of AR-42 (formerly OSU-HDAC42) at The Ohio State University Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) in adult patients with relapsed or refractory multiple myeloma (MM), chronic lymphocytic leukemia (CLL) or lymphoma. The primary objective of this Phase I/IIa, open-label, single-agent dose escalation study is to evaluate the safety and tolerability of oral AR-42 by establishing the maximum tolerated dose (MTD). The secondary objectives include characterizing the pharmacokinetics of the compound, evaluating pharmacodynamic changes in patient biomarkers, and assessing preliminary efficacy of AR-42 in the defined patient population. The Phase I/IIa study is anticipated to enroll up to approximately 50 patients in two phases. The first phase is designed to identify the MTD of the drug, and the second phase will further explore the activity at this MTD dose by enrolling 10 patients into each of three MM, CLL, and lymphoma sub-groups. Craig Hofmeister, M.D., a hematologist and oncologist at OSUCCC-James, is the principal investigator for this single-site clinical trial.